An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice

The adenosine analogue galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, has entered a phase 1 clinical safety and pharmacokinetics study in healthy subjects and is under clinical development for treatment of Ebola and yellow fever virus infections. Moreover, galidesivir also inhibits the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Virol
Autori principali: Eyer, Ludek, Nougairède, Antoine, Uhlířová, Marie, Driouich, Jean-Sélim, Zouharová, Darina, Valdés, James J., Haviernik, Jan, Gould, Ernest A., De Clercq, Erik, de Lamballerie, Xavier, Ruzek, Daniel
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2019
Soggetti:
Vaccines and Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675905/
https://ncbi.nlm.nih.gov/pubmed/31142664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00367-19
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi